Evidence map›Paper›PMID 32231166›Full record

ArticleMolecules (Basel, Switzerland)2020

5-Alkylamino-

Weronika Ambrożkiewicz, Marta Kučerová-Chlupáčová, Ondřej Janďourek, Klára Konečná, Pavla Paterová, Pavel Bárta, Jarmila Vinšová, Martin Doležal, Jan Zitko

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. TargetingACS omega · 2026
    Article
  2. Review
  3. Design, Synthesis and Antimicrobial Evaluation of NewInternational journal of molecular sciences · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Weronika AmbrożkiewiczFaculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.ORCID 0000-0001-8119-1491
Marta Kučerová-ChlupáčováFaculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.ORCID 0000-0002-8656-0740
Ondřej JanďourekFaculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.ORCID 0000-0003-4633-2062
Klára KonečnáFaculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.ORCID 0000-0001-5670-7767
Pavla PaterováDepartment of Clinical Microbiology, University Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic.
Pavel BártaFaculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.ORCID 0000-0001-5445-5658
Jarmila VinšováFaculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
Martin DoležalFaculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.ORCID 0000-0003-1558-6625
Jan ZitkoFaculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.ORCID 0000-0003-0104-9925
Charles University · CZUniversity Hospital Hradec Králové · CZ

Funding

Grantová Agentura České Republiky 20-19638YMinisterstvo Školství, Mládeže a Tělovýchovy CZ.02.1.01/0.0/0.0/16_019/0000841
6 · The paper itself

Abstract

According to the World Health Organization, tuberculosis is still in the top ten causes of death from a single infectious agent, killing more than 1.7 million people worldwide each year. The rising resistance developed by

Indexed as

Antitubercular AgentsDrug DesignDrug DevelopmentHumansMicrobial Sensitivity TestsMycobacterium tuberculosisPyrazinamidePyrazinesStructure-Activity RelationshipAntitubercular AgentsPyrazinamidePyrazinesalkylamino derivativesantibacterialantifungalantimycobacterialcytotoxicitypyrazinamide

Identifiers

PMID32231166
PMCPMC7180572
OpenAlexW3013727897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.